Darbepoetin alfa as primary prophylaxis of anemia in patients with breast cancer treated preoperatively with docetaxel/doxorubicin/cyclophosphamide

Supportive Cancer Therapy

Volumn 3, Issue 2, 2006, Pages 103-109

  Loibl, Sibylle ^a,b   Kaufmann, Manfred ^a   Maataoui, Vidya ^a   Mehta, Keyur M ^b   Hofmann, Katharina ^a   Petrich, Simone ^a   Von Minckwitz, Gunter ^a,b  

^a GOETHE UNIVERSITY   (Germany)

^b German Breast Group   (Germany)

Author keywords

Chemotherapy; Erythropoiesis; Erythropoietin; Fatigue; Hemoglobin

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HUMAN; PREOPERATIVE TREATMENT; PROPHYLAXIS;

EID: 33645964635     PISSN: 15432912     EISSN: None     Source Type: Journal    
DOI: 10.3816/SCT.2006.n.006     Document Type: Article

References (25)

1. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999; 91:1616-1634.
2. Harper P, Littlewood T. Anaemia of cancer: impact on patient fatigue and long-term outcome. Oncology 2005; 69(suppl 2):2-7.
3. Demetri GD. Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy. Br J Cancer 2001; 84(suppl 1):31-37.
4. Caro JJ, Salas M, Ward A, et al. Anemia as an independent prognostic factor for survival in patients with cancer. Cancer 2001; 91:2214-2221.
5. Littlewood TJ, Bajetta E, Nortier JWR, et al. Effects of epoetin alfa on hematologic parameters and quality of live in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19:2865-2874.
6. Vansteenkiste J, Pirket R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. Aranesp 980297 Study Group. J Natl Cancer Inst 2002; 94:1211-1220.
7. Blohmer JU, Würschmidt F, Petry U, et al. 6th interim analysis of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study: sequential adjuvant chemo-radiotherapy with vs. without erythropoietin for patients with high-risk cervical cancer. Proc Am Soc Clin Oncol 2003; 22:447 (Abstract #1798).
8. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362:1255-1260.
9. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005; 23:5960-5972.
10. Österborg A, Brandberg Y, Molostova V, et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002; 20:2486-2494.
11. Egrie JC, Dwyer E, Browne JK, et al. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003; 31:290-299.
12. Egrie J, Browne J. Darbepoetin alfa is more potent in vivo and can be administered less frequently than rHuEPO. Br J Cancer 2002; 87:476-477.
13. von Minckwitz G, Blohmer JU, Raab G, et al. In vivo chemosensitivity- adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 2005; 16:56-63.
14. Cella D. The functional assessment of cancer therapy-anemia (FACT-An) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997; 34:13-19.
15. Kotasek D, Steger G, Faught W, et al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Aranesp 980291 Study Group. Eur J Cancer 2003; 39:2026-2034.
16. Glaspy J, Henry D, Patel R, et al. Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer 2005; 41:1140-1149.
17. Glaspy JA, Jadeja JS, Justice G, et al. A randomized, active-control, pilot trial of front loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease. Cancer 2003; 97:312-1320.
18. Kotasek D, Canon JL, San Miguel J, et al. Correction/maintenance dosing (front loading) of darbepoetin alfa: final results form a randomized phase 3 active controlled trial. Blood 2004; 104:455a (Abstract #1636).
19. von Minckwitz G, Raab G, Caputo A, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 2005; 23:2676-2685.
20. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. Breast Cancer International Research Group 001 Investigators. New Engl J Med 2005; 352:2346-2348.
21. Nabholtz JM, Cantin J, Chang J, et al. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial. Clin Breast Cancer 2002; 4:268-275.
22. Bohlius J, Langensiepen S, Schwarzer G, et al. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 2005; 97:489-498.
23. Langer CJ, Williams D. Anemia correction and hemoglobin maintenance with epoetin alfa 60,000 U qw followed by 80,000 q3w in anemic patients with cancer receiving chemotherapy. Blood 2003; 102:166b (Abstract #4372).
24. Shasha D, Henry DH, Williams D. Early results suggest that epoetin alfa 60,000 U every 2 weeks improves hemoglobin in patients with cancer not receiving chemotherapy or radiotherapy. Blood 2004; 104:141b (Abstract #4222).
25. Kaufmann M, von Minckwitz G, Smith R, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 2003; 21:2600-2608.